THE DUAL ACTION

Survodutide

Grade B — Good

Next-generation dual GLP-1/glucagon agonist for enhanced weight loss and metabolic benefits.

Also known as: BI 456906

Weight Loss
Metabolic Health
GLP-1
Glucagon
Dual Agonist

Overview

Survodutide is a cutting-edge dual agonist that activates both GLP-1 and glucagon receptors. This dual action may provide superior weight loss compared to GLP-1-only drugs like Semaglutide, while also improving liver health and metabolic markers. It's currently in late-stage clinical trials and showing very promising results for both obesity and fatty liver disease.

Dosing Guide

Dosage

0.6mg to 4.8mg weekly (dose escalation)

Schedule

daily

Cycle

Weekly injection, continuous use

Pro Tip

Follow slow dose escalation to minimize GI side effects

Safety Profile

B

Clinical Trials

Good

Currently in Phase 3 trials with promising safety data so far.

Investigational compound. Not yet FDA approved. Use with caution and medical supervision.

Possible Side Effects

Nausea
Vomiting
Diarrhea
Decreased appetite

Who Is This For

Those seeking maximum weight loss potential
People with fatty liver disease (NASH/MAFLD)
Individuals who plateau on single-agonist GLP-1s
Early adopters of next-gen metabolic therapies

Related Peptides

Liraglutide

A

THE DAILY

FDA-approved GLP-1 for weight loss and blood sugar control with daily dosing.

Adipotide

C

THE FAT BURNER

Targets and destroys fat cells by cutting off their blood supply.

Ready to Start Your Peptide Journey?

Track your protocols, get guided reconstitution, and access our vetted vendor network — all in one app.

Download The Peptide App